We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Roche Diagnostics

Develops, manufactures, and markets a wide range of in vitro diagnostic systems, instruments, reagents, and tests read more Featured Products: More products

Download Mobile App




C-Reactive Protein Predicts Neurological Outcomes of Subarachnoid Hemorrhage Patients

By LabMedica International staff writers
Posted on 07 Apr 2020
Subarachnoid hemorrhage (SAH) is a disease associated with high mortality. More...
Survivors of SAH may manifest severe neurological deficits. In patients with SAH, early brain injury or delayed cerebral ischemia (DCI) is associated with poor outcomes.

C-reactive protein (CRP) is a useful marker of non-specific inflammation. Elevated CRP levels might be associated with the progression of vascular disease. Elevated levels of CRP are significantly associated with unfavorable long-term functional outcome in patients with ischemic stroke. The measurement of CRP significantly increases the ability to make accurate predictions and prevent or manage coronary thrombotic events appropriately.

Neurologists at the Samsung Medical Center (Seoul, Republic of Korea) carried out a retrospective, single-center, observational study of adult patients with SAH who were admitted to the neurosurgical intensive care unit (ICU) from January 2012 through June 2017. A total of 156 patients diagnosed with SAH were analyzed in the study. Initial brain CT and CT angiography were performed within 12 hours from the onset of SAH.

Initial CRP levels were measured within 12 hours after admission. The day of admission was defined as day 1. CRP data on days 1 to 7 were collected. Serum CRP levels were measured using the CRPL3 immunoturbidimetric assays (Roche Diagnostics, Indianapolis, IN, USA) with a lower reference limit of 0.3 mg/dL. The maximal level of CRP (CRPMax) was defined as the peak level from days 1 through 4. Subsequent CRP (CRPmin) level was determined as the minimal level from days 5 to 7.

The scientists reported that among 156 patients with SAH, 145 (92.9%) survived until discharge. Of these survivors, 109 (69.9%) manifested favorable neurological outcomes. Initial CRP levels on admission and maximal CRP levels within four days were significantly higher in the group with poor neurological outcome compared with those manifesting favorable neurological outcomes. Prediction of poor neurological outcome showed that the performance of the maximal CRP was significantly better compared with the initial CRP or the clearance of CRP. The maximal CRP levels within four days facilitate the prediction of neurological outcomes of SAH patients without surgical clipping.

The authors concluded that early serial measurements of CRP may be used to predict neurological outcomes of SAH patients. Furthermore, maximal CRP levels within four days post-SAH are significantly correlated with poor neurological outcomes. The study was published on march 27, 2020 in the journal BMC Neurology.

Related Links:
Samsung Medical Center
Roche Diagnostics



Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Online QC Software
Acusera 24•7
Automated Urinalysis Solution
UN-9000
Steam Sterilizer
Hi Vac II Line
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The SimpleScreen CRC platform uses multiomics, AI, and machine learning to analyze blood-based signals and detect cancer-associated patterns (Photo courtesy of Freenome)

Blood Test Achieves Improved Detection of Advanced Precancerous Colorectal Lesions

Colorectal cancer is the second-leading cause of cancer-related death in the United States, yet screening uptake remains suboptimal. More than 50 million eligible adults are not up to date with recommended... Read more

Hematology

view channel
Image Credit: Shutterstock

New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more

Immunology

view channel
Image:Proteomic tear-fluid analysis revealed abnormal patterns in proteins that regulate nerves and T cells in individuals with eye problems (Image Credit: Adobe Stock)

Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19

Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more

Industry

view channel
Photo courtesy of Natera

Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing

Natera’s Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR), becoming the first personalized MRD test for solid tumors to achieve... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.